文献速递血栓与止血

前瞻性血友病抑制剂PUP研究揭示FVIII抑制剂产生前的独特抗体特征

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.
PubMed 文献 · Blood Adv · 2020-01-01

HIPS是首个在重型血友病A患者首次暴露于FVIII后50个暴露日内前瞻性评估免疫系统全面变化的研究,入组者为真正未暴露患者。纵向抗体数据显示患者可分为4个亚组,具有不同的FVIII结合抗体特征,其中IgG3出现始终与持续性抑制剂相关,部分抗体特征可能作为早期生物标志物。

要点

  • HIPS研究识别出4种FVIII结合抗体特征亚组,亚组1无FVIII结合IgG,亚组2仅非中和性IgG1,亚组3为一过性抑制剂伴IgG1,亚组4为持续性抑制剂伴高亲和力IgG1后出现IgG3和IgG4。
  • FVIII结合IgG3的出现始终与持续性FVIII抑制剂及后续IgG4产生相关。
  • 部分抗体特征可能作为FVIII抑制剂开发的早期生物标志物候选。

核心结论

  • HIPS研究揭示重型血友病A患者首次FVIII暴露后存在4种不同的FVIII结合抗体特征亚组,部分特征可能作为早期抑制剂生物标志物。

研究设计与样本

  • 前瞻性队列研究HIPS(NCT01652027),纳入重型血友病A真正未暴露患者,在首次暴露于单一重组FVIII后50个暴露日内指定时间点评估免疫学和临床参数。

主要发现

  • 亚组1未产生可检测的FVIII结合IgG抗体。
  • 亚组2产生非中和性FVIII结合IgG1抗体,未观察到其他FVIII结合IgG亚类。
  • 亚组3产生一过性FVIII抑制剂,伴FVIII结合IgG1抗体,与亚组2相似。
  • 亚组4产生持续性FVIII抑制剂,初始出现高亲和力FVIII结合IgG1抗体,随后出现IgG3和IgG4抗体。
  • FVIII结合IgG3的出现始终与持续性FVIII抑制剂及后续FVIII结合IgG4产生相关。

临床怎么用

  • FVIII结合IgG3的出现可能提示持续性抑制剂风险,部分抗体特征可作为早期生物标志物候选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII inhibitors is essential for risk identification and the design of novel strategies to prevent inhibitor development. The Hemophilia Inhibitor Previously Untreated Patients (PUPs) Study (HIPS; www.clinicaltrials.gov #NCT01652027) is the first prospective cohort study to evaluate comprehensive changes in the immune system during the first 50 exposure days (EDs) to FVIII in patients with severe hemophilia A. HIPS participants were enrolled prior to their first exposure to FVIII or blood products ("true PUPs") and were evaluated for different immunological and clinical parameters at specified time points during their first 50 EDs to a single source of recombinant FVIII. Longitudinal antibody data resulting from this study indicate that there are 4 subgroups of patients expressing distinct signatures of FVIII-binding antibodies. Subgroup 1 did not develop any detectable FVIII-binding immunoglobulin G (IgG) antibodies. Subgroup 2 developed nonneutralizing, FVIII-binding IgG1 antibodies, but other FVIII-binding IgG subclasses were not observed. Subgroup 3 developed transient FVIII inhibitors associated with FVIII-binding IgG1 antibodies, similar to subgroup 2. Subgroup 4 developed persistent FVIII inhibitors associated with an initial development of high-affinity, FVIII-binding IgG1 antibodies, followed by IgG3 and IgG4 antibodies. Appearance of FVIII-binding IgG3 was always associated with persistent FVIII inhibitors and the subsequent development of FVIII-binding IgG4. Some of the antibody signatures identified in HIPS could serve as candidates for early biomarkers of FVIII inhibitor development.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Reipert BM, Gangadharan B, Hofbauer CJ, et al. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Adv. 2020. PMID: 33232473. doi:10.1182/bloodadvances.2020002731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。